Xinjingzhiyuan Biotechnology
A company focusing on the development of TCR-T immune cell therapy drugs for solid tumors.
Launch date
Market cap
-
Enterprise valuation
AUD170—255m (Dealroom.co estimates Mar 2023.)
China (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
* | CNY200m | Series A | |
| Total Funding | AUD42.5m | ||